Case Reports in Oncology (Jun 2020)

Ramadan Fasting in a Patient with Chronic Myeloid Leukemia Receiving Nilotinib as Upfront

  • Husam N. Al-Dubai,
  • Mohammed A. Yassin,
  • Mohammed A. Abdulla,
  • Mahmood S. Aldapt,
  • Rola S. Ghassoub

DOI
https://doi.org/10.1159/000507508
Journal volume & issue
Vol. 13, no. 2
pp. 664 – 667

Abstract

Read online

Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm classically described as triphasic disease: chronic, accelerated, and blast crisis. There are many unmet needs and unanswered questions about CML. Intermittent fasting in patients with CML on tyrosine kinase inhibitors is among these unmet needs. Here we report the effect of intermittent fasting on response to nilotinib as upfront in a 49-year-old female Muslim who fasted during Ramadan and took her medication once instead of twice daily and remained in major molecular response.

Keywords